electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

Rhea-AI Summary

On May 24, 2022, electroCore (Nasdaq: ECOR) announced that its gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available at over 130 National Spine and Pain Centers (NSPC) locations across the U.S. This partnership aims to enhance patient access to non-opioid pain management solutions for primary headaches. Mitch DeShon from electroCore emphasized the importance of collaboration with NSPC to improve treatment outcomes, while NSPC's mission focuses on alleviating unnecessary pain through innovative therapies. GammaCore is FDA cleared and CE-marked for various headache treatments.

Positive

• Expansion of gammaCore availability through partnership with NSPC, increasing patient access.
• Collaboration with NSPC reinforces electroCore's strategy to enhance market penetration and adoption of nVNS therapy.

Negative

• None.

ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with different forms of primary headache.

“National Spine and Pain Center’s mission is to end needless human pain and suffering by facilitating minimally invasive and non invasive approaches to pain management,” says clinical President Mark Coleman of National Spine and Pain Centers. “nVNS therapy fits into the goal of providing better outcomes by offering innovative, state of the art, non opioid strategies to improve function and alleviate acute and chronic pain.”

“We are excited to be working with National Spine and Pain Centers as we expand patient access to our therapy,” commented Mitch DeShon, electroCore’s Vice President of US Sales. “NSPC is one of the Company’s first corporate accounts and serves as an example of how national healthcare organizations and electroCore could work together to expand adoption of gammaCore nVNS for sufferers of primary headache, and reinforces the Company’s strategy of providing patients with greater access to our nVNS therapy through healthcare providers or directly via our online stores.”

About National Spine and Pain Centers
For more than 30 years, NSPC affiliated physicians have been pioneers in the relief of chronic and acute pain through minimally invasive procedures and leading-edge clinical research. Today, with more than 130 locations and 1,250 affiliated medical professionals facilitating one million patient visits a year, NSPC continues to be the healthcare brand more people trust for access to pain relief providers than any other. NSPC’s stated mission is to end needless human pain and suffering by facilitating world-class care.

For more information, visit www.NationalSpine.com.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.

About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients if they:

• Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
• Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
• Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
  

Safety and efficacy of gammaCore have not been evaluated in the following patients:

• Adolescent patients with congenital cardiac issues
• Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
• Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
• Pediatric patients (less than 12 years)
• Pregnant women
• Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

For more information, please visit gammaCore.com

Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects through NSPC and other new corporate accounts or other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

Contact:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital

FAQ

What is the significance of electroCore's partnership with National Spine and Pain Centers?

The partnership allows electroCore to expand the availability of its gammaCore Sapphire™ device, increasing access to non-invasive pain management solutions for primary headaches.

When was gammaCore Sapphire™ announced for distribution by NSPC?

The announcement was made on May 24, 2022.

What conditions does gammaCore Sapphire™ treat?

GammaCore Sapphire™ is indicated for the preventive treatment of cluster headache and migraine, as well as for the acute treatment of pain associated with these conditions.

How does gammaCore's nVNS therapy work?

GammaCore uses mild electrical stimulation applied at the neck to activate the vagus nerve, potentially reducing pain associated with migraines and cluster headaches.

Is gammaCore FDA approved?

Yes, gammaCore is FDA cleared for multiple headache treatments and is CE-marked in the European Union.